Trade Protectionism

Showing 1636 articles
Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.

Business

CITIC Telecom CFO Steps Down: Leadership Shift Puts Governance, Dividend Strategy in Focus

The resignation of CITIC Telecom International Holdings' CFO and Executive Director Luan Zhenjun, effective January 2026, marks a significant change in the company's financial leadership. While the immediate operational impact may be limited, the move raises questions about governance continuity and capital allocation discipline at a time when the stock trades at a perceived discount to its fair value.

Business

Analysts Bullish on American Tower's 2026 Outlook Despite Price Target Adjustments

Wall Street maintains a positive stance on American Tower Corporation (AMT) as it enters 2026, with over 70% of analysts recommending the stock. While several firms have trimmed price targets citing sector headwinds, the long-term outlook for the communications infrastructure giant remains favorable, driven by its data center portfolio and stable tower business.